

COVID-19 Impact on Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size, Status and Forecast 2020-2026

<https://marketpublishers.com/r/CF4F6D6B981AEN.html>

Date: July 2020

Pages: 152

Price: US\$ 3,900.00 (Single User License)

ID: CF4F6D6B981AEN

Abstracts

This report focuses on the global Targeted Drug EGFR RTK Inhibitors for NSCLC status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Targeted Drug EGFR RTK Inhibitors for NSCLC development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

Beta Pharma

AstraZeneca

Natco Pharma

Qilu Pharmaceutical

Genentech (Roche Group)

Mylan

Teva

OSI Pharmaceuticals

Glenmark Pharmaceuticals

Beacon Pharmaceuticals

Boehringer Ingelheim

Pfizer

ARIAD Pharmaceuticals (Takeda)

Genvio Pharma Limited

Drug International Limited

Everest Pharmaceuticals

Incepta Pharmaceuticals Limited

Cipla Pharma

Dr Reddy's Laboratories

Zydus Cadila

Hetero Drugs

Intas Pharmaceuticals

Alkem Laboratories

RPG Life Sciences

Fresenius Kabi India

Market segment by Type, the product can be split into

Icotinib

Gefitinib

Erlotinib

Afatinib

Osimertinib

Brigatinib

Other

Market segment by Application, split into

Squamous Cell Carcinoma of NSCLC

Adenocarcinoma of NSCLC

Large Cell Carcinoma of NSCLC

Market segment by Regions/Countries, this report covers

North America

Europe

China

Japan

Southeast Asia

India

Central & South America

The study objectives of this report are:

To analyze global Targeted Drug EGFR RTK Inhibitors for NSCLC status, future forecast, growth opportunity, key market and key players.

To present the Targeted Drug EGFR RTK Inhibitors for NSCLC development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

To strategically profile the key players and comprehensively analyze their development plan and strategies.

To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Targeted Drug EGFR RTK Inhibitors for NSCLC are as follows:

History Year: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope

1.2 Key Market Segments

1.3 Players Covered: Ranking by Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue

1.4 Market Analysis by Type

1.4.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate by Type: 2020 VS 2026

1.4.2 Icotinib

1.4.3 Gefitinib

1.4.4 Erlotinib

1.4.5 Afatinib

1.4.6 Osimertinib

1.4.7 Brigatinib

1.4.8 Other

1.5 Market by Application

1.5.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application: 2020 VS 2026

1.5.2 Squamous Cell Carcinoma of NSCLC

1.5.3 Adenocarcinoma of NSCLC

1.5.4 Large Cell Carcinoma of NSCLC

1.6 Coronavirus Disease 2019 (Covid-19): Targeted Drug EGFR RTK Inhibitors for NSCLC Industry Impact

1.6.1 How the Covid-19 is Affecting the Targeted Drug EGFR RTK Inhibitors for NSCLC Industry

1.6.1.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Business Impact Assessment - Covid-19

1.6.1.2 Supply Chain Challenges

1.6.1.3 COVID-19's Impact On Crude Oil and Refined Products

1.6.2 Market Trends and Targeted Drug EGFR RTK Inhibitors for NSCLC Potential Opportunities in the COVID-19 Landscape

1.6.3 Measures / Proposal against Covid-19

1.6.3.1 Government Measures to Combat Covid-19 Impact

1.6.3.2 Proposal for Targeted Drug EGFR RTK Inhibitors for NSCLC Players to Combat Covid-19 Impact

1.7 Study Objectives

1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Perspective (2015-2026)

2.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Growth Trends by Regions

2.2.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Regions: 2015 VS 2020 VS 2026

2.2.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Historic Market Share by Regions (2015-2020)

2.2.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Regions (2021-2026)

2.3 Industry Trends and Growth Strategy

2.3.1 Market Top Trends

2.3.2 Market Drivers

2.3.3 Market Challenges

2.3.4 Porter's Five Forces Analysis

2.3.5 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Growth Strategy

2.3.6 Primary Interviews with Key Targeted Drug EGFR RTK Inhibitors for NSCLC Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC Players by Market Size

3.1.1 Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC Players by Revenue (2015-2020)

3.1.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Players (2015-2020)

3.1.3 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

3.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Concentration Ratio

3.2.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Concentration Ratio (CR5 and HHI)

3.2.2 Global Top 10 and Top 5 Companies by Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue in 2019

3.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players Head office and Area Served

3.4 Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Product Solution and Service

3.5 Date of Enter into Targeted Drug EGFR RTK Inhibitors for NSCLC Market

3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Historic Market Size by Type (2015-2020)

4.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Type (2021-2026)

5 TARGETED DRUG EGFR RTK INHIBITORS FOR NSCLC BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020)

5.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2015-2020)

6.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in North America (2019-2020)

6.3 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020)

6.4 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2015-2020)

7.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in Europe (2019-2020)

7.3 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020)

7.4 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020)

8 CHINA

- 8.1 China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2015-2020)
- 8.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in China (2019-2020)
- 8.3 China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020)
- 8.4 China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020)

9 JAPAN

- 9.1 Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2015-2020)
- 9.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in Japan (2019-2020)
- 9.3 Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020)
- 9.4 Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

- 10.1 Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2015-2020)
- 10.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in Southeast Asia (2019-2020)
- 10.3 Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020)
- 10.4 Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020)

11 INDIA

- 11.1 India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2015-2020)
- 11.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in India (2019-2020)
- 11.3 India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020)
- 11.4 India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2015-2020)

12.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in Central & South America (2019-2020)

12.3 Central & South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020)

12.4 Central & South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Beta Pharma

13.1.1 Beta Pharma Company Details

13.1.2 Beta Pharma Business Overview and Its Total Revenue

13.1.3 Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction

13.1.4 Beta Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020))

13.1.5 Beta Pharma Recent Development

13.2 AstraZeneca

13.2.1 AstraZeneca Company Details

13.2.2 AstraZeneca Business Overview and Its Total Revenue

13.2.3 AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction

13.2.4 AstraZeneca Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

13.2.5 AstraZeneca Recent Development

13.3 Natco Pharma

13.3.1 Natco Pharma Company Details

13.3.2 Natco Pharma Business Overview and Its Total Revenue

13.3.3 Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction

13.3.4 Natco Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

13.3.5 Natco Pharma Recent Development

13.4 Qilu Pharmaceutical

13.4.1 Qilu Pharmaceutical Company Details

13.4.2 Qilu Pharmaceutical Business Overview and Its Total Revenue

13.4.3 Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction

13.4.4 Qilu Pharmaceutical Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

13.4.5 Qilu Pharmaceutical Recent Development

13.5 Genentech (Roche Group)

13.5.1 Genentech (Roche Group) Company Details

13.5.2 Genentech (Roche Group) Business Overview and Its Total Revenue

13.5.3 Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC

Introduction

13.5.4 Genentech (Roche Group) Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

13.5.5 Genentech (Roche Group) Recent Development

13.6 Mylan

13.6.1 Mylan Company Details

13.6.2 Mylan Business Overview and Its Total Revenue

13.6.3 Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction

13.6.4 Mylan Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

13.6.5 Mylan Recent Development

13.7 Teva

13.7.1 Teva Company Details

13.7.2 Teva Business Overview and Its Total Revenue

13.7.3 Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction

13.7.4 Teva Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

13.7.5 Teva Recent Development

13.8 OSI Pharmaceuticals

13.8.1 OSI Pharmaceuticals Company Details

13.8.2 OSI Pharmaceuticals Business Overview and Its Total Revenue

13.8.3 OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC

Introduction

13.8.4 OSI Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

13.8.5 OSI Pharmaceuticals Recent Development

13.9 Glenmark Pharmaceuticals

13.9.1 Glenmark Pharmaceuticals Company Details

13.9.2 Glenmark Pharmaceuticals Business Overview and Its Total Revenue

13.9.3 Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC

Introduction

13.9.4 Glenmark Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

13.9.5 Glenmark Pharmaceuticals Recent Development

13.10 Beacon Pharmaceuticals

13.10.1 Beacon Pharmaceuticals Company Details

13.10.2 Beacon Pharmaceuticals Business Overview and Its Total Revenue

13.10.3 Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC

Introduction

13.10.4 Beacon Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

13.10.5 Beacon Pharmaceuticals Recent Development

13.11 Boehringer Ingelheim

10.11.1 Boehringer Ingelheim Company Details

10.11.2 Boehringer Ingelheim Business Overview and Its Total Revenue

10.11.3 Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC

Introduction

10.11.4 Boehringer Ingelheim Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

10.11.5 Boehringer Ingelheim Recent Development

13.12 Pfizer

10.12.1 Pfizer Company Details

10.12.2 Pfizer Business Overview and Its Total Revenue

10.12.3 Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction

10.12.4 Pfizer Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

10.12.5 Pfizer Recent Development

13.13 ARIAD Pharmaceuticals (Takeda)

10.13.1 ARIAD Pharmaceuticals (Takeda) Company Details

10.13.2 ARIAD Pharmaceuticals (Takeda) Business Overview and Its Total Revenue

10.13.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction

10.13.4 ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

10.13.5 ARIAD Pharmaceuticals (Takeda) Recent Development

13.14 Genvio Pharma Limited

10.14.1 Genvio Pharma Limited Company Details

10.14.2 Genvio Pharma Limited Business Overview and Its Total Revenue

10.14.3 Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC

Introduction

10.14.4 Genvio Pharma Limited Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

10.14.5 Genvio Pharma Limited Recent Development

13.15 Drug International Limited

10.15.1 Drug International Limited Company Details

10.15.2 Drug International Limited Business Overview and Its Total Revenue

10.15.3 Drug International Limited Targeted Drug EGFR RTK Inhibitors for NSCLC

Introduction

10.15.4 Drug International Limited Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

10.15.5 Drug International Limited Recent Development

13.16 Everest Pharmaceuticals

10.16.1 Everest Pharmaceuticals Company Details

10.16.2 Everest Pharmaceuticals Business Overview and Its Total Revenue

10.16.3 Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC

Introduction

10.16.4 Everest Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

10.16.5 Everest Pharmaceuticals Recent Development

13.17 Incepta Pharmaceuticals Limited

10.17.1 Incepta Pharmaceuticals Limited Company Details

10.17.2 Incepta Pharmaceuticals Limited Business Overview and Its Total Revenue

10.17.3 Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for

NSCLC Introduction

10.17.4 Incepta Pharmaceuticals Limited Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

10.17.5 Incepta Pharmaceuticals Limited Recent Development

13.18 Cipla Pharma

10.18.1 Cipla Pharma Company Details

10.18.2 Cipla Pharma Business Overview and Its Total Revenue

10.18.3 Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction

10.18.4 Cipla Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

10.18.5 Cipla Pharma Recent Development

13.19 Dr Reddy's Laboratories

10.19.1 Dr Reddy's Laboratories Company Details

10.19.2 Dr Reddy's Laboratories Business Overview and Its Total Revenue

10.19.3 Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC

Introduction

10.19.4 Dr Reddy's Laboratories Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

10.19.5 Dr Reddy's Laboratories Recent Development

13.20 Zydus Cadila

10.20.1 Zydus Cadila Company Details

10.20.2 Zydus Cadila Business Overview and Its Total Revenue

10.20.3 Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction

10.20.4 Zydus Cadila Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

10.20.5 Zydus Cadila Recent Development

13.21 Hetero Drugs

10.21.1 Hetero Drugs Company Details

10.21.2 Hetero Drugs Business Overview and Its Total Revenue

10.21.3 Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction

10.21.4 Hetero Drugs Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

10.21.5 Hetero Drugs Recent Development

13.22 Intas Pharmaceuticals

10.22.1 Intas Pharmaceuticals Company Details

10.22.2 Intas Pharmaceuticals Business Overview and Its Total Revenue

10.22.3 Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction

10.22.4 Intas Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

10.22.5 Intas Pharmaceuticals Recent Development

13.23 Alkem Laboratories

10.23.1 Alkem Laboratories Company Details

10.23.2 Alkem Laboratories Business Overview and Its Total Revenue

10.23.3 Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction

10.23.4 Alkem Laboratories Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

10.23.5 Alkem Laboratories Recent Development

13.24 RPG Life Sciences

10.24.1 RPG Life Sciences Company Details

10.24.2 RPG Life Sciences Business Overview and Its Total Revenue

10.24.3 RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction

10.24.4 RPG Life Sciences Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

10.24.5 RPG Life Sciences Recent Development

13.25 Fresenius Kabi India

10.25.1 Fresenius Kabi India Company Details

10.25.2 Fresenius Kabi India Business Overview and Its Total Revenue

10.25.3 Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC

Introduction

10.25.4 Fresenius Kabi India Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

10.25.5 Fresenius Kabi India Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.2 Data Source

15.2 Disclaimer

15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Targeted Drug EGFR RTK Inhibitors for NSCLC Key Market Segments

Table 2. Key Players Covered: Ranking by Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue

Table 3. Ranking of Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC Manufacturers by Revenue (US\$ Million) in 2019

Table 4. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate by Type (US\$ Million): 2020 VS 2026

Table 5. Key Players of Icotinib

Table 6. Key Players of Gefitinib

Table 7. Key Players of Erlotinib

Table 8. Key Players of Afatinib

Table 9. Key Players of Osimertinib

Table 10. Key Players of Brigatinib

Table 11. Key Players of Other

Table 12. COVID-19 Impact Global Market: (Four Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast Scenarios)

Table 13. Opportunities and Trends for Targeted Drug EGFR RTK Inhibitors for NSCLC Players in the COVID-19 Landscape

Table 14. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis

Table 15. Key Regions/Countries Measures against Covid-19 Impact

Table 16. Proposal for Targeted Drug EGFR RTK Inhibitors for NSCLC Players to Combat Covid-19 Impact

Table 17. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth by Application (US\$ Million): 2020 VS 2026

Table 18. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Regions (US\$ Million): 2020 VS 2026

Table 19. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Regions (2015-2020) (US\$ Million)

Table 20. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Regions (2015-2020)

Table 21. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Regions (2021-2026) (US\$ Million)

Table 22. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Regions (2021-2026)

Table 23. Market Top Trends

Table 24. Key Drivers: Impact Analysis

Table 25. Key Challenges

Table 26. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Growth Strategy

Table 27. Main Points Interviewed from Key Targeted Drug EGFR RTK Inhibitors for NSCLC Players

Table 28. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Players (2015-2020) (Million US\$)

Table 29. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Players (2015-2020)

Table 30. Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC as of 2019)

Table 31. Global Targeted Drug EGFR RTK Inhibitors for NSCLC by Players Market Concentration Ratio (CR5 and HHI)

Table 32. Key Players Headquarters and Area Served

Table 33. Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Product Solution and Service

Table 34. Date of Enter into Targeted Drug EGFR RTK Inhibitors for NSCLC Market

Table 35. Mergers & Acquisitions, Expansion Plans

Table 36. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US\$)

Table 37. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Share by Type (2015-2020)

Table 38. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Type (2021-2026)

Table 39. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Share by Application (2015-2020)

Table 40. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US\$)

Table 41. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Share by Application (2021-2026)

Table 42. North America Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (2019-2020) (Million US\$)

Table 43. North America Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share (2019-2020)

Table 44. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US\$)

Table 45. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2015-2020)

Table 46. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US\$)

Table 47. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2015-2020)

Table 48. Europe Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (2019-2020) (Million US\$)

Table 49. Europe Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share (2019-2020)

Table 50. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US\$)

Table 51. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2015-2020)

Table 52. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US\$)

Table 53. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2015-2020)

Table 54. China Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (2019-2020) (Million US\$)

Table 55. China Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share (2019-2020)

Table 56. China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US\$)

Table 57. China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2015-2020)

Table 58. China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US\$)

Table 59. China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2015-2020)

Table 60. Japan Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (2019-2020) (Million US\$)

Table 61. Japan Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share (2019-2020)

Table 62. Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US\$)

Table 63. Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2015-2020)

Table 64. Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US\$)

Table 65. Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by

Application (2015-2020)

Table 66. Southeast Asia Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (2019-2020) (Million US\$)

Table 67. Southeast Asia Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share (2019-2020)

Table 68. Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US\$)

Table 69. Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2015-2020)

Table 70. Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US\$)

Table 71. Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2015-2020)

Table 72. India Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (2019-2020) (Million US\$)

Table 73. India Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share (2019-2020)

Table 74. India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US\$)

Table 75. India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2015-2020)

Table 76. India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US\$)

Table 77. India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2015-2020)

Table 78. Central & South America Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (2019-2020) (Million US\$)

Table 79. Central & South America Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share (2019-2020)

Table 80. Central & South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US\$)

Table 81. Central & South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2015-2020)

Table 82. Central & South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US\$)

Table 83. Central & South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2015-2020)

Table 84. Beta Pharma Company Details

Table 85. Beta Pharma Business Overview

- Table 86. Beta Pharma Product
- Table 87. Beta Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US\$)
- Table 88. Beta Pharma Recent Development
- Table 89. AstraZeneca Company Details
- Table 90. AstraZeneca Business Overview
- Table 91. AstraZeneca Product
- Table 92. AstraZeneca Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US\$)
- Table 93. AstraZeneca Recent Development
- Table 94. Natco Pharma Company Details
- Table 95. Natco Pharma Business Overview
- Table 96. Natco Pharma Product
- Table 97. Natco Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US\$)
- Table 98. Natco Pharma Recent Development
- Table 99. Qilu Pharmaceutical Company Details
- Table 100. Qilu Pharmaceutical Business Overview
- Table 101. Qilu Pharmaceutical Product
- Table 102. Qilu Pharmaceutical Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US\$)
- Table 103. Qilu Pharmaceutical Recent Development
- Table 104. Genentech (Roche Group) Company Details
- Table 105. Genentech (Roche Group) Business Overview
- Table 106. Genentech (Roche Group) Product
- Table 107. Genentech (Roche Group) Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US\$)
- Table 108. Genentech (Roche Group) Recent Development
- Table 109. Mylan Company Details
- Table 110. Mylan Business Overview
- Table 111. Mylan Product
- Table 112. Mylan Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US\$)
- Table 113. Mylan Recent Development
- Table 114. Teva Company Details
- Table 115. Teva Business Overview
- Table 116. Teva Product
- Table 117. Teva Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US\$)

- Table 118. Teva Recent Development
- Table 119. OSI Pharmaceuticals Business Overview
- Table 120. OSI Pharmaceuticals Product
- Table 121. OSI Pharmaceuticals Company Details
- Table 122. OSI Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US\$)
- Table 123. OSI Pharmaceuticals Recent Development
- Table 124. Glenmark Pharmaceuticals Company Details
- Table 125. Glenmark Pharmaceuticals Business Overview
- Table 126. Glenmark Pharmaceuticals Product
- Table 127. Glenmark Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US\$)
- Table 128. Glenmark Pharmaceuticals Recent Development
- Table 129. Beacon Pharmaceuticals Company Details
- Table 130. Beacon Pharmaceuticals Business Overview
- Table 131. Beacon Pharmaceuticals Product
- Table 132. Beacon Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US\$)
- Table 133. Beacon Pharmaceuticals Recent Development
- Table 134. Boehringer Ingelheim Company Details
- Table 135. Boehringer Ingelheim Business Overview
- Table 136. Boehringer Ingelheim Product
- Table 137. Boehringer Ingelheim Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US\$)
- Table 138. Boehringer Ingelheim Recent Development
- Table 139. Pfizer Company Details
- Table 140. Pfizer Business Overview
- Table 141. Pfizer Product
- Table 142. Pfizer Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US\$)
- Table 143. Pfizer Recent Development
- Table 144. ARIAD Pharmaceuticals (Takeda) Company Details
- Table 145. ARIAD Pharmaceuticals (Takeda) Business Overview
- Table 146. ARIAD Pharmaceuticals (Takeda) Product
- Table 147. ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US\$)
- Table 148. ARIAD Pharmaceuticals (Takeda) Recent Development
- Table 149. Genvio Pharma Limited Company Details
- Table 150. Genvio Pharma Limited Business Overview

- Table 151. Genvio Pharma Limited Product
- Table 152. Genvio Pharma Limited Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US\$)
- Table 153. Genvio Pharma Limited Recent Development
- Table 154. Drug International Limited Company Details
- Table 155. Drug International Limited Business Overview
- Table 156. Drug International Limited Product
- Table 157. Drug International Limited Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US\$)
- Table 158. Drug International Limited Recent Development
- Table 159. Everest Pharmaceuticals Company Details
- Table 160. Everest Pharmaceuticals Business Overview
- Table 161. Everest Pharmaceuticals Product
- Table 162. Everest Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US\$)
- Table 163. Everest Pharmaceuticals Recent Development
- Table 164. Incepta Pharmaceuticals Limited Company Details
- Table 165. Incepta Pharmaceuticals Limited Business Overview
- Table 166. Incepta Pharmaceuticals Limited Product
- Table 167. Incepta Pharmaceuticals Limited Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US\$)
- Table 168. Incepta Pharmaceuticals Limited Recent Development
- Table 169. Cipla Pharma Company Details
- Table 170. Cipla Pharma Business Overview
- Table 171. Cipla Pharma Product
- Table 172. Cipla Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US\$)
- Table 173. Cipla Pharma Recent Development
- Table 174. Dr Reddy's Laboratories Company Details
- Table 175. Dr Reddy's Laboratories Business Overview
- Table 176. Dr Reddy's Laboratories Product
- Table 177. Dr Reddy's Laboratories Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US\$)
- Table 178. Dr Reddy's Laboratories Recent Development
- Table 179. Zydus Cadila Company Details
- Table 180. Zydus Cadila Business Overview
- Table 181. Zydus Cadila Product
- Table 182. Zydus Cadila Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US\$)

Table 183. Zydus Cadila Recent Development

Table 184. Hetero Drugs Company Details

Table 185. Hetero Drugs Business Overview

Table 186. Hetero Drugs Product

Table 187. Hetero Drugs Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US\$)

Table 188. Hetero Drugs Recent Development

Table 189. Intas Pharmaceuticals Company Details

Table 190. Intas Pharmaceuticals Business Overview

Table 191. Intas Pharmaceuticals Product

Table 192. Intas Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US\$)

Table 193. Intas Pharmaceuticals Recent Development

Table 194. Alkem Laboratories Company Details

Table 195. Alkem Laboratories Business Overview

Table 196. Alkem Laboratories Product

Table 197. Alkem Laboratories Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US\$)

Table 198. Alkem Laboratories Recent Development

Table 199. RPG Life Sciences Company Details

Table 200. RPG Life Sciences Business Overview

Table 201. RPG Life Sciences Product

Table 202. RPG Life Sciences Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US\$)

Table 203. RPG Life Sciences Recent Development

Table 204. Fresenius Kabi India Company Details

Table 205. Fresenius Kabi India Business Overview

Table 206. Fresenius Kabi India Product

Table 207. Fresenius Kabi India Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US\$)

Table 208. Fresenius Kabi India Recent Development

Table 209. Research Programs/Design for This Report

Table 210. Key Data Information from Secondary Sources

Table 211. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type: 2020 VS 2026

Figure 2. Icotinib Features

Figure 3. Gefitinib Features

Figure 4. Erlotinib Features

Figure 5. Afatinib Features

Figure 6. Osimertinib Features

Figure 7. Brigatinib Features

Figure 8. Other Features

Figure 9. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application: 2020 VS 2026

Figure 10. Squamous Cell Carcinoma of NSCLC Case Studies

Figure 11. Adenocarcinoma of NSCLC Case Studies

Figure 12. Large Cell Carcinoma of NSCLC Case Studies

Figure 13. Targeted Drug EGFR RTK Inhibitors for NSCLC Report Years Considered

Figure 14. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth 2015-2026 (US\$ Million)

Figure 15. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Regions: 2020 VS 2026

Figure 16. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Regions (2021-2026)

Figure 17. Porter's Five Forces Analysis

Figure 18. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Players in 2019

Figure 19. Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC as of 2019)

Figure 20. The Top 10 and 5 Players Market Share by Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue in 2019

Figure 21. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US\$)

Figure 22. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US\$)

Figure 23. China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US\$)

Figure 24. Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US\$)

Figure 25. Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US\$)

Figure 26. India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US\$)

Figure 27. Central & South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US\$)

Figure 28. Beta Pharma Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 29. Beta Pharma Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

Figure 30. AstraZeneca Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 31. AstraZeneca Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

Figure 32. Natco Pharma Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 33. Natco Pharma Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

Figure 34. Qilu Pharmaceutical Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 35. Qilu Pharmaceutical Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

Figure 36. Genentech (Roche Group) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 37. Genentech (Roche Group) Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

Figure 38. Mylan Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 39. Mylan Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

Figure 40. Teva Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 41. Teva Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

Figure 42. OSI Pharmaceuticals Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 43. OSI Pharmaceuticals Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

Figure 44. Glenmark Pharmaceuticals Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 45. Glenmark Pharmaceuticals Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

Figure 46. Beacon Pharmaceuticals Total Revenue (US\$ Million): 2019 Compared with

2018

Figure 47. Beacon Pharmaceuticals Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

Figure 48. Boehringer Ingelheim Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 49. Boehringer Ingelheim Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

Figure 50. Pfizer Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 51. Pfizer Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

Figure 52. ARIAD Pharmaceuticals (Takeda) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 53. ARIAD Pharmaceuticals (Takeda) Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

Figure 54. Genvio Pharma Limited Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 55. Genvio Pharma Limited Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

Figure 56. Drug International Limited Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 57. Drug International Limited Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

Figure 58. Everest Pharmaceuticals Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 59. Everest Pharmaceuticals Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

Figure 60. Incepta Pharmaceuticals Limited Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 61. Incepta Pharmaceuticals Limited Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

Figure 62. Cipla Pharma Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 63. Cipla Pharma Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

Figure 64. Dr Reddy's Laboratories Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 65. Dr Reddy's Laboratories Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)

Figure 66. Zydus Cadila Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 67. Zydus Cadila Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors

for NSCLC Business (2015-2020)

Figure 68. Bottom-up and Top-down Approaches for This Report

Figure 69. Data Triangulation

Figure 70. Key Executives Interviewed

I would like to order

Product name: COVID-19 Impact on Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size, Status and Forecast 2020-2026

Product link: <https://marketpublishers.com/r/CF4F6D6B981AEN.html>

Price: US\$ 3,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CF4F6D6B981AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

